Effect of different @entity7828 in low XXXX oral contraceptives on @entity1211 . World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

@entity455 @entity64 @entity2081 @entity2931 @entity2082 @entity6862 @entity2692 @entity7828 @entity7281 @entity583 @entity7280 @entity1211
A multinational hospital-based case-control study of the risk of @entity1211 associated with combined @entity7280 ( @entity6862 ) done in 1989-93 prompted a separate inquiry comparing the risk of @entity1211 ( @entity1211 ) associated with low @entity2931 (< 35 micrograms @entity2082 ) @entity6862 containing @entity2692 with risks in low @entity2931 preparations containing the third-generation @entity7828 @entity7281 or @entity2081 . This analysis of data from 9 countries, involved 769 cases and 1979 age matched hospital controls and, in one centre, 246 community controls matched on age and general practice. 137 cases and 203 controls were current users of @entity2692 (odds ratio [OR with 95% confidence interval] 3.5 [2.6-4.7]), with non-users as the reference; 35 cases and 28 controls were current users of @entity7281 (9.1 [4.9-17.0]), and 36 cases and 28 controls were current users of @entity2081 (9.1 [4.9-16.7]). The ratios of these risks, compared with @entity2692 , were 2.6 (1.4-4.8) for both products separately. Risk estimates adjusted for body mass index (BMI) were 3.4, 7.3, and 10.2 for @entity2692 , @entity7281 , and @entity2081 , respectively, compared with non-users, and 2.2 and 3.0 for @entity7281 and @entity2081 , respectively, compared with @entity2692 . 48 (68%) cases and 48 (86%) controls exposed to @entity7281 or @entity2081 were from the UK (Oxford region). In this centre risk estimates compared with non-users, adjusted for BMI, were 2.6, 5.3, and 5.7 for @entity2692 , @entity7281 , and @entity2081 , respectively. Current users of low @entity2931 dose combined @entity6862 containing @entity7281 or @entity2081 appear to be at higher risk of @entity1211 than users of combined @entity6862 containing @entity2692 . The possibility that these unexpected results on a secondary study objective are due to chance, bias, or residual confounding cannot be excluded entirely and the results need to be confirmed by independent studies. They are at variance with the apparently more favourable metabolic effects of the newer @entity7828 . Whether the new @entity7828 are associated with lower risk of @entity455 ( @entity64 and @entity583 ) must be evaluated further.
